Novartis feels heat from copycat drugs

Novartis has felt the dampening effect of generic drugs at the start of the year. Nevertheless, management confirmed its previous outlook for the further course of business. + Get the most important news from Switzerland in your inbox Turnover for the first quarter totalled $13.1 billion, a decrease of 1% compared to the same period last year. At constant exchange rates, the decline was 5%. By comparison, revenue in the final quarter of 2025 was still up by 1% and in the third quarter of the year by 8%. According to its own earlier statements, the pharmaceutical group will experience the heaviest burden from copycat drugs in its history in the coming months because the billion-euro drugs Entresto, Promacta and Tasigna have lost their patent protection. CEO Vas Narasimhan estimated the impact on sales at around $4 billion at the beginning of February. The impact is likely to be significantly greater in the first half of the year, he added. The Basel-based company recorded a 9% drop ... Full story here Are you the author? Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: Featured,global trade,newsletter